CLICK HERE if you are a Consumer
Galderma
Roll Over for Important Safety Information
Metrogel: The one with the Enhanced Formulation for exceptional tolerability

  • In patient satisfaction questionnaire analysis, patients favored MetroGel® 1% and 84.4% said that they were likely to use it in the future compared with 79.9% for azelaic acid 15% gel


  • Only 4.4% of patients experienced treatment-related adverse events which resolved quickly


  • Patients treated with MetroGel® 1% were significantly less bothered with side effects than patients using azelaic acid 15% gel


  • 74% of patients said they were not bothered at all by treatment side effects (vs. 52.7% for azelaic acid 15 gel)


  • Patients treated with MetroGel® 1% experienced significantly lower incidences of burning and stinging than patients using azelaic acid 15% gel


  • There is low potential for hypopigmentation associated with the use of MetroGel® 1%


  • Patients treated with MetroGel® 1% were significantly less bothered with side effects than patients using azelaic acid 15% gel


  • Adverse events reported and associated with metronidazole 1% gel treatment included conjunctivitis, abdominal pain, facial pain, hypoesthesia, rosacea flare and skin desquamation

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

Important Safety Information

MetroGel® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea. MetroGel® 1% gel is contraindicated in individuals with a history of hypersensitivity to metronidazole or any other ingredients in this formulation. For more information about MetroGel®, see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.